Friedrichs, M. (2023). A web-based annotation tool for clinical trial failure reasons. GMS Medizinische Informatik, Biometrie Und Epidemiologie, 19, Doc02. doi: 10.3205/mibe000241

Filter:

Trial ID Phase Status Type
Results Reported Result Refs Exist Enrollment From To
Free Text
Annotations

7805 Trials matched filter criteria

Status:   Withdrawn   Suspended   Terminated
Trial Updated /
Type
Status Phase Were
Results
Reported
Reported
Actual
Enrollment
(MeSH) Terms Why Stopped
Limitations And Caveats
Annotator decisions
NCT00630370
Details
2009-06-17
Interventional
26 
ATI 7505
Syndrome Post Prandial D…
-
-
NCT00501241
Details
2009-06-17
Interventional
2-
ATI 7505
Constipation Chronic Constip…
-
-
NCT00397657
Details
2009-06-17
Interventional
4-
Ezetimibe Niacin
Atherosclerosis
Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.
-
NCT00915616
Details
2009-06-08
Interventional
3-
Melatonin
Gastroesophagea… Gastroesophagea…
-
-
NCT00251095
Details
2009-06-04
Interventional
3821 
Paclitaxel
Breast Neoplasm… Breast Neoplasm
Failed primary endpoint
-
NCT00904852
Details
2009-05-20
Interventional
1-
Bevacizumab Temozolomide
Glioblastoma Glioblastoma Mu…
-
-
NCT00436722
2005-005635-10
Details
2009-05-20
Interventional
2-
Antilymphocyte … Immunoglobulins
Liver Diseases
Experimental arm (induction + low dose tacrolimus) not effective.
-
NCT00297076
Details
2009-05-18
Interventional
3-
Aplaviroc
HIV Infections HIV Infection
-
-
NCT00437489
Details
2009-05-11
Interventional
449 
Insulin Insulin, Globin…
Diabetes Mellit… Diabetes Mellit…
This protocol was terminated not for safety reasons, but because Pfizer decided to return the worldwide rights for Exubera to Nektar, on 18 October 2007.
As a result of Pfizer's decision (18Oct2007) to return the worldwide rights for Exubera (insulin human [rDNA origin]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study.
NCT00683267
Details
2009-05-04
Interventional
2118 
Capsaicin
Arthroplasty
Enrollment of patients has halted prematurely and will not resume. No future patients will be enrolled or treated.
-
NCT00672568
Details
2009-05-04
Interventional
224 
Capsaicin
Rotator Cuff Re…
Study has been halted after completing Stage 1, for corporate reasons. No future patients will be enrolled or treated.
-
NCT00435448
Details
2009-04-29
Interventional
3-
Lonidamine
Hyperplasia Prostatic Hyper… Benign Prostati… Enlarged Prosta…
-
-
NCT00237536
Details
2009-04-29
Interventional
2-
Lonidamine
Hyperplasia Prostatic Hyper… Benign Prostati…
-
-
NCT00496158
Details
2009-04-27
Interventional
3-
Adefovir Clevudine
Hepatitis Hepatitis A Hepatitis B Hepatitis, Chro… Chronic Hepatit…
The study was terminated in the interest of patient safety.
-
NCT00496002
Details
2009-04-27
Interventional
3-
Adefovir Clevudine
Hepatitis Hepatitis A Hepatitis B Hepatitis, Chro… Chronic Hepatit…
The study was terminated in the interest of patient safety.
-
NCT00237900
Details
2009-04-23
Interventional
1/2-
Fluorouracil Gefitinib Leucovorin
Stomach Neoplas… Subjects With R…
-
-
NCT00261352
Details
2009-04-22
Interventional
3-
Fenofibrate Metformin
Diabetes Mellit… Type 2 Diabetes
The development program has been terminated
-
NCT00251953
2004-000348-25
Details
2009-04-22
Interventional
3-
Metformin
Diabetes Mellit… Type 2 Diabetes
The development program has been terminated
-
NCT00242372
Details
2009-04-22
Interventional
3-
Insulin
Diabetes Mellit… Type 2 Diabetes…
The development program has been terminated
-
NCT00710216
Details
2009-04-20
Interventional
4-
Lamivudine Telbivudine
Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch…
Sponsor withdraw
-